Myofascial Pain Disorders: Theory to Therapy

Drugs

Volumn 64, Issue 1, 2004, Pages 45-62

  Wheeler, Anthony H ^a,b  

^a Charlotte Spine Center   (United States)

^b Pain and Orthopedic Neurology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANESTHETIC AGENT; BOTULINUM TOXIN; CELECOXIB; CORTICOSTEROID; DICLOFENAC; ETODOLAC; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXAPROZIN; PHENTOLAMINE; PIROXICAM; SPASMOLYTIC AGENT; SULINDAC; TIZANIDINE; TOLMETIN; TRICYCLIC ANTIDEPRESSANT AGENT; TROMETAMOL; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANOREXIA; ASTHENIA; ATAXIA; BIOMECHANICS; CHEMOTHERAPY; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONVALESCENCE; DENERVATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIZZINESS; DROWSINESS; EDEMA; ELECTROMYOGRAM; FATIGUE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MECHANICAL STIMULATION; MUSCLE LENGTH; MUSCLE STRENGTH; MUSCLE STRETCHING; MUSCLE TONE; MYALGIA; MYOFASCIAL PAIN; NAUSEA; NEPHROTOXICITY; NERVE TRANSECTION; NERVOUSNESS; NEUROPHYSIOLOGY; NONHUMAN; PALPATION; PATHOGENESIS; PRACTICE GUIDELINE; REFLEX DISORDER; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPINAL REFLEX; TACHYCARDIA; THEORY; THERMAL STIMULATION; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; ANESTHETICS, LOCAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; BOTULINUM TOXINS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL; MYOFASCIAL PAIN SYNDROMES; RANDOMIZED CONTROLLED TRIALS;

ATAXIA;

EID: 1642533548     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464010-00004     Document Type: Review

References (103)

1. Simons DG, Travell JG, Simons LS. Travell and Simons' myofascial pain and dysfunction: the trigger point manual. 2nd ed. Baltimore (MD): Williams & Wilkins, 1999
2. Fishbain DA, Goldberg M, Meagher BR, et al. Male and female chronic pain patient's categories by DSM-III psychiatric diagnostic criteria. Pain 1986; 26: 181-97
3. Gerwin RD. A study of 96 subjects examined both for fibromyalgia and myofascial pain [abstract]. J Musculoskeletal Pain 1995; 3 Suppl. 1: 121
4. Drewes AM, Jennum P. Epidemiology of myofascial pain, low back pain, morning stiffness and sleep-related complaints in the general population [abstract]. J Muscoskeletal Pain 1995; 3 Suppl. 1: G8
5. Bonica J. The management of pain. Vol. 1. 2nd ed. Philadelphia (PA): Lea & Febiger, 1990: 180-96
6. Magni G. The epidemiology of musculoskeletal pain. In: Voeroy H, Merskey H, editors. Progress in fibromyalgia and myofascial pain. Amsterdam: Elsevier Science, 1993: 3-20
7. Bohr T. Problems with myofascial pain syndrome and fibromyalgia syndrome. Neurology 1996; 79: 593-7
8. Wheeler AH, Aaron GW. Muscle pain due to injury. Curr Pain Headache Rep 2001; 5: 441-6
9. Noonan TJ, Garrett WE. Muscle strain injury: diagnosis and treatment. J Am Acad Orthop Surg 1999; 7: 262-9
10. Wheeler AH, Murrey DB. Chronic lumbar spine and radicular pain: pathophysiology and treatment. Curr Pain Headache Rep 2002; 6: 97-105
11. Frymoyer JW. Back pain and sciatica. N Engl J Med 1988; 318: 291-300
12. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33: 160-72
13. Pillemer SR, Bradley LA, Crofford LI, et al. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997; 40: 1703-7
14. Urban MO, Gebhart GF. Central mechanisms in pain. Med Clin North Am 1999; 83: 585-96
15. Carlton SM, Zhou S, Coggeshal RE. Evidence for the interaction of glutamate and NK1 receptors in the periphery. Brain Res 1998; 83: 160-9
16. Bennett RM. Emerging concepts in the neurobiology of chronic pain; evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999; 74: 385-98
17. Fields HL. Pain. New York: McGraw-Hill, 1987
18. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997; 386 (6626): 721-4
19. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993; 18: 1803-7
20. Hubbard DR. Chronic and recurrent muscle pain: pathophysiology and treatment, and review of pharmacologic studies. J Musculoskeletal Pain 1996; 4: 123-43
21. Rivner MH. The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 2000; 5: 432-40
22. Brown WF, Varkey GP. The origin of spontaneous electrical activity at the end-plate zone. Ann Neurol 1981; 10: 557-60
23. Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskeletal Pain 1996; 4: 61-92
24. Pappagallo M. Aggressive pharmacologic treatment of pain. Rheum Dis Clin North Am 1999; 25: 193-209
25. Davidoff RA. Trigger points and myofascial pain: toward understanding how they affect headaches. Cephalalgia 1998; 18: 436-48
26. Cyriax J. Textbook of orthopaedic medicine: diagnosis of soft tissue lesions. 8th ed. Baltimore (MD): Williams & Wilkins, 1984
27. Cantu RI, Grodin AJ. Myofascial manipulation: theory and clinical application. Gaithersburg (MD): Aspen, 1992
28. Magee DJ. Orthopedic physical assessment. 2nd ed. Philadelphia (PA): WB Saunders, 1992
29. Galer BS, Dworkin RH. A clinical guide to neuropathic pain. Minneapolis (MN): McGraw-Hill, 2000
30. Downer AH. Physical therapy procedures. Springfield (IL): Charles C Thomas, 1970
31. Lee JM, Warren MP, Mason SM. Effects of ice on nerve conduction velocity. Physiotherapy 1978; 64: 2-6
32. Waylonis GW. The physiological effects of ice massage. Arch Phys Med Rehabil 1967; 48: 37-42
33. Wheeler AH, Hanley EN. Nonoperative treatment of low back pain: rest to restoration. Spine 1995; 20: 375-8
34. Argoff CE, Wheeler AH. Spinal and radicular pain disorders. Neurol Clin 1998; 4: 833-49
35. Deyo RA. Nonoperative treatment of low back disorders: differentiated useful from useless therapy. In: Frymoyer JW, Ducker TB, Hadler NM, et al., editors. The adult spine principles and practice. Philadelphia (PA): Lippincott-Raven, 1997: 1777-93
36. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45
37. Silverstein F, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The class study: a randomized controlled trial. JAMA 2000; 284 (10): 1247-55
38. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520-8
39. Enffaard TP, Kiltgaard NA, Gram LF, et al. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 2001; 69 (4): 245-51
40. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001; 35 (5): 557-9
41. Harkens S, Linford J, Cohen J, et al. Administration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study. J Craniomandib Disord 1991; 5 (3): 179-86
42. Fromm GH, Terence CF, Chatta AS. Baclofen in the treatment of trigeminal neuralgia. Ann Neurol 1984; 15: 240-7
43. Waldman SD. Recent advances in analgesic therapy: tizanidine. Pain Digest 1999; 9: 40-3
44. Wagstaff AJ, Bryson HM. Tizanidine: a review of pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 436-51
45. Muramatsu I, Kigoshi G. Tizanidine may discriminate between imidazoline-receptors and adrenoreceptor. Jpn J Pharmacol 1992; 59: 457-9
46. Milanov I, Georgiev D. Mechanisms of tizanidine in spasticity. Acta Neurol Scand 1994; 89: 274-9
47. Wiesendanger M, Corboz M, Palmeri A, et al. Noradrenergic mechanisms involved in muscle relaxation: significance for the treatment of spasticity. Schweiz Acta Neurol Psychiatr 1991; 142 (2): 132-4
48. Ono H, Mishima A, Ono S, et al. Inhibitory effects of clonidine and tizanidine on release of substance P. Neuropharmacology 1991; 30: 585-9
49. Lataste X, Emre M, Davis C, et al. Comparative profile of tizanidine in the management of spasticity. Neurology 1994; 44: 53-9
50. Berry H, Hutchinson DR. A multicenter placebo-controlled study in general practice to evaluate the safety and efficacy of tizanidine in acute low back pain. J Int Med Res 1988; 16: 75-82
51. Felder M. Tizanidine in the treatment of neck and low back pain. AIDS Int 1990; 1: 9
52. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low back pain: results of a multicenter double-blind study in general practice. J Int Med Res 1988; 16: 83-91
53. Fryda-Kaurimsky Z, Muller-Fassbender H. Tizanidine in the treatment of acute paravertebral spasms: a controlled trial comparing tizanidine with diazepam. J Int Med Res 1981; 9: 501-5
54. Tse FLS, Jaffe JM, Bhuta S. Pharmacokinetics of tizanidine in health volunteers. Fundam Clin Pharmacol 1987; 1: 479-88
55. Rosenberg JM, Harrell C, Rishi H, et al. The effect of gabapentin on neuropathic pain. Clin J Pain 1997; 13: 251-5
56. Bardin M, Chantelauze C, Lavarenne J, et al. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994; 57: 153-60
57. McCain GA. Fibromyalgia and myofascial pain syndromes. In: Wall PD, Melzack R, editors. Textbook of pain. 3rd ed. New York: Churchill Livingstone, 1994: 475-93
58. Jay GW. Chronic daily headache: pathophysiology and treatment. Pain Digest 1994; 16: 851-68
59. Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine 1996; 21: 2840-50
60. Lipman AG. Analgesic drugs for neuropathic and sympathetically maintained pain. Clin Geriatr Med 1996; 12: 501-15
61. McQuay HJ, Moore RA, Eccleston C, et al. Systemic review of outpatient services for chronic pain control. Health Technol Assess 1997; 1 (6): i-iv, 1-135
62. Garcia J, Altman RD. Chronic pain states: pathophysiology and medical therapy. Semin Arthritis Rheum 1997; 27: 1-16
63. + channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284: 208-14
64. Reveille JD. Soft-tissue rheumatism: diagnosis and treatment. Am J Med 1997; 102 Suppl. 1A: 23S-9S
65. Wasner G, Backonja M-M, Baron R. Traumatic neuralgias: complex regional pain syndromes (reflex sympathetic dystrophy and causalgia): clinical characteristics, pathophysiologic mechanisms and therapy. Neurol Clin 1998; 16: 851-68
66. Bonezzi C, Demartini L. Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl 1999; 173: 25-35
67. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400
68. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16 (2 Suppl.): S49-55
69. Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 2000; 40: 83-102
70. Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. J Craniomandibular Pract 1997; 15: 53-6
71. Jacobson LO, Bley K, Hunter JC, et al. Anti-thermal hyperalgesic properties of antidepressants in a rat model of neuropathic pain [abstract]. American Pain Society Annual Meeting; 1995 Sep 9-12; Los Angeles (CA)
72. Taylor K, Rowbotham MC. Venlafaxine for chronic pain [abstract]. American Pain Society Annual Meeting: 1995 Sep 9-12; Los Angeles (CA)
73. Wheeler AH. Therapeutic injections for pain management. In: Mendozabal J, Talavera F, Halsey JH, et al., editors. Neurology section of EMedicine [textbook online; updated 2000 Mar 2]. Available from URL: http://emedicine.com/ neuro/topic514.htm [Accessed 2003 Sep 20]
74. Bonica JJ, Buckley FO. Regional anesthesia with local anesthetics. In: Bonica JJ, Loeser JD, Chapman RC, et al., editors. The management of pain. 2nd ed. Philadelphia (PA): Lea & Febiger, 1990: 1883-1966
75. Brown DL. Atlas of regional anesthesia. Philadelphia (PA): WB Samuels, 1992
76. Garvey TA, Marks MR, Wiesel SW. A prospective, randomized double-blind evaluation of trigger-point injection therapy for low-back pain. Spine 1989; 14: 962-4
77. Dreyer SJ. Commonly used medications in pain procedures. In: Lennard JA, editor. Pain procedures in clinical practice. Philadelphia (PA): Hanley & Belfus, 2000: 1-9
78. Criscuolo CM. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001; 5: 407-11
79. Lacy CF, Armstrong LL, Goldman MP, et al. Drug information handbook. Hudson (OH): Lexi-Comp, 1999
80. Noerdlinger MA, Fadale PD. The role of injectable corticosteroids in orthopedics. Orthopedics 2001; 24 (4): 400-5
81. Wiggins ME, Fadale PD, Barrach H, et al. Healing characteristics of a type I collagenous structure treated with corticosteroids. Am J Sports Med 1994; 22: 279-88
82. Cohen IK, Diegelmann RF, Johnson ML. Effect of corticosteroids on collagen synthesis. Surgery 1977; 82: 15-20
83. Jankovic J, Brin JF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 342: 1186-94
84. Wheeler AH. The therapeutic uses of botulinum toxin. Am Fam Physician 1997; 55: 541-5
85. Guyer BA. Mechanism of botulinum toxin the in relief of chronic pain. Curr Rev Pain 1993; 3: 427-31
86. Wheeler AH, Goolkasian P. Open label assessment of botulinum toxin A for pain treatment in a private outpatient setting. J Musculoskeletal Pain 2001; 9: 67-82
87. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160-3
88. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-5
89. O'Brien CF. Clinical applications of botulinum toxin: implications for pain management. Pain Digest 1998; 8: 342-5
90. Zwart JA, Bovim G, Sand T, et al. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 1994; 34: 458-62
91. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997; 4 Suppl. 2: S71-3
92. Hobson D, Gladish D. Botulinum toxin injection for cervicogenic headache. Headache 1997; 36: 253-5
93. Wheeler AH. Botulinum toxin-A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998; 38: 468-71
94. Cheshire WP, Abashjan SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65-9
95. Yue SK. Initial experience in the use of botulinum toxin A for the treatment of myofascial related muscle dysfunction. J Musculoske Pain 1995; 3 Suppl. 1: 22
96. Wheeler AH, Goolkasian P, Gretz SS. A randomized double-blind prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic paraspinal, myofascial pain syndrome. Spine 1998; 23: 1662-7
97. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001; 94: 255-60
98. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000; 85: 101-5
99. Freund BJ, Schwartz M. Treatment of whiplash associated with neck pain with botulinum toxin-A: a pilot study. J Rheumatol 2000; 27: 481-4
100. Royal MA, Gunyeu I, Bhatia B, et al. Botulinum toxin type A in the treatment of refractory myofascial pain [abstract]. Neurology 2001; 58 Suppl. 3: A350
101. Lang AM. A pilot study of botulinum toxin type A (botox), administered using a novel technique, for the treatment of myofascial pain. Am J Pain Med 2000; 10: 108-12
102. Wheeler AH. Botulinum toxin injection technique for treatment of headaches. Aesthetic Surg J 2002; 22: 65-8
103. Schneider P, Mororu E, Bitttner C, et al. Physical therapy and botulinum toxin type A in patients with cervical associated headache according to IHS-criteria: double-blind placebo-controlled study [abstract]. Neurology 2001; 58 Suppl. 3: A349